ISOSORBIDE DINITRATE Drug Patent Profile
✉ Email this page to a colleague
When do Isosorbide Dinitrate patents expire, and when can generic versions of Isosorbide Dinitrate launch?
Isosorbide Dinitrate is a drug marketed by Impax Labs Inc, Sun Pharm Inds Inc, Ani Pharms, Hikma Intl Pharms, Par Pharm, Par Pharm Inc, Rubicon, Sandoz, Sun Pharm Industries, Superpharm, Watson Labs, Zydus, Watson Labs Teva, I3 Pharms, and Riconpharma Llc. and is included in thirty-six NDAs.
The generic ingredient in ISOSORBIDE DINITRATE is hydralazine hydrochloride; isosorbide dinitrate. There are twenty-one drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the hydralazine hydrochloride; isosorbide dinitrate profile page.
Summary for ISOSORBIDE DINITRATE
US Patents: | 0 |
Applicants: | 15 |
NDAs: | 36 |
Finished Product Suppliers / Packagers: | 19 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Clinical Trials: | 29 |
Patent Applications: | 3,901 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ISOSORBIDE DINITRATE |
What excipients (inactive ingredients) are in ISOSORBIDE DINITRATE? | ISOSORBIDE DINITRATE excipients list |
DailyMed Link: | ISOSORBIDE DINITRATE at DailyMed |
Recent Clinical Trials for ISOSORBIDE DINITRATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Copenhagen University Hospital, Hvidovre | Phase 4 |
Johannes Grand | Phase 4 |
Bispebjerg Hospital | Phase 4 |
Pharmacology for ISOSORBIDE DINITRATE
Drug Class | Nitrate Vasodilator |
Physiological Effect | Vasodilation |